While Poly-L Lactic Acid (PLLA/Sculptra® Aesthetic) has been used for non-facial volumization for some time now, there’s a lot of safety precautions that need to be considered to reach the best possible patient outcomes. Reviewing best practices for the off-label use of PLLA are Dr. Sabrina Fabi and Dr. Neil Sadick.

Disclaimer: The list of available dermal fillers is continuously evolving. Since this activity was produced, some products are no longer approved by the US FDA or currently marketed, while others have received regulatory approval. Providers are highly encouraged to click on this link to view the FDA’s updated list of injectable available: Dermal Fillers Approved by the Center for Devices and Radiological Health.

Using Poly-L Lactic Acid (PLLA/Sculptra®Aesthetic) gives you the ability to enhance your patients’ facial volume—but only when done correctly. Here to review the best practices for using PLLA on the most common areas of the face are Dr. Sabrina Fabi and Dr. Rebecca Fitzgerald.

Disclaimer: The list of available dermal fillers is continuously evolving. Since this activity was produced, some products are no longer approved by the US FDA or currently marketed, while others have received regulatory approval. Providers are highly encouraged to click on this link to view the FDA’s updated list of injectable available: Dermal Fillers Approved by the Center for Devices and Radiological Health.

This innovative, 30-minute, case-based CME activity provides an opportunity for participants to evaluate the clinical issues and recent data regarding anticoagulation in patients with coronary artery disease (CAD) and peripheral artery disease (PAD). The program covers challenges faced by healthcare providers in caring for patients with polyvascular disease. Topics include:

• COMPASS: Putting Data into Perspective
• COMMANDER: Anticoagulation in Patients with HF and CAD
• MARINER: Anticoagulation Data

Not only do serious exacerbations interfere with a patient’s daily activities, but they also account for much of the morbidity and mortality associated with asthma, as well as at least half of asthma-related costs. That’s why clinicians need information about new research to optimize their management of patients with severe asthma.

Live from the CHEST Annual Meeting in San Antonio, TX, Dr. Jennifer Caudle is joined by pulmonary experts Dr. Eugene Bleeker, Dr. Mario Castro, and Dr. Nicola Hanania to discuss the emerging science of severe asthma, new approaches to its treatment, and what the future might hold for clinicians and their patients.

This innovative, 30-minute, CME activity features 5 leading experts addressing complex issues when treating patients with residual cardiovascular disease (CVD) risk, using triglyceride-rich lipoprotein (TGRL) science and management. The program is based on a live satellite symposium (held during the time of AHA-2018), where REDUCE-IT results were 1st presented after a late-breaking clinical trial presentation. Challenges faced by healthcare providers in caring for patients with elevated TGRL are addressed. Topics include:

• Central Role of Triglyceride-rich Lipoproteins (TGRL) in CVD Residual Risk beyond Statin Therapy
• Biologic Basis for TGRL Modulation in Reducing Atherosclerosis
• Clinical Evidence on Reducing TGRL-based Residual Risk: REDUCE-IT

For more information, contact Medtelligence, LLC at [email protected].

This activity will discuss approaches that enable physicians to perform hysteroscopic surgery more safely and effectively by focusing on best practices, overcoming operative difficulties, and the inclusion of pharmacologic agents that improve visualization, reduce vascularity, and lower the possibility of hyponatremia.

This activity will discuss the numerous elements that make up the updated diagnostic and treatment algorithm to manage abnormal uterine bleeding, including using a minimally invasive surgical approach, having a better understanding of the broad umbrella of bleeding that occurs outside of normal cyclic menstruation, performing proper patient workups, and more.

To help you ensure the safe and effective use of tissue morcellation during hysteroscopic and abdominal procedures, this activity will focus on the guidelines, evolutions in the procedure, and the risks versus benefits of adopting this technique.

This activity will discuss the numerous elements that make up the updated diagnostic and treatment algorithm to manage abnormal uterine bleeding, including using a minimally invasive surgical approach, having a better understanding of the broad umbrella of bleeding that occurs outside of normal cyclic menstruation, performing proper patient workups, and more.

Whenever the topic of establishing minimally invasive hysteroscopic surgery in the office setting comes up, many physicians ask why and how. Leveraging decades of professional experience, this activity answers those questions by reviewing the necessary training and staff requirements, the procedures that are most beneficial for your patients, the path to accruing a patient and referral base, and most importantly, maintaining patient safety while ensuring pain control with optimal outcomes.